Biomarkers of atherosclerotic plaque instability and rupture
Standard
Biomarkers of atherosclerotic plaque instability and rupture. / Koenig, Wolfgang; Khuseyinova, Natalie.
in: ARTERIOSCL THROM VAS, Jahrgang 27, Nr. 1, 01.2007, S. 15-26.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Biomarkers of atherosclerotic plaque instability and rupture
AU - Koenig, Wolfgang
AU - Khuseyinova, Natalie
PY - 2007/1
Y1 - 2007/1
N2 - Basic research over the last two decades has identified a large number of molecules pertinent to the atherosclerotic process, which have clearly improved our understanding of the underlying pathology. It is now well established that inflammation represents a major feature which is present in the vessel wall throughout all stages of the disease until the final pathophysiologic steps, representing plaque destabilization and eventually plaque rupture. Several cells typical for the atherosclerotic plaque, like monocyte-derived macrophages and T-lymphocytes are able to produce and secrete such mediator molecules, like cytokines, chemokines, growth-factors, enzymes, and disintegrins, which lead to activation of endothelial cells, proliferation of smooth muscle cells, lesion progression, and finally to the weakening of a vulnerable plaque by matrix degradation of its fibrous cap. Today, many of these molecules involved can be measured systemically by sensitive assays, and elevated concentrations in the circulation have been shown to be associated with future cardiovascular events. Determination of several of these molecules carries important prognostic information, independent of traditional risk factors, and may turn out to be useful in improving risk stratification. However, for most of these biomarkers the clinical utility has not yet been established.
AB - Basic research over the last two decades has identified a large number of molecules pertinent to the atherosclerotic process, which have clearly improved our understanding of the underlying pathology. It is now well established that inflammation represents a major feature which is present in the vessel wall throughout all stages of the disease until the final pathophysiologic steps, representing plaque destabilization and eventually plaque rupture. Several cells typical for the atherosclerotic plaque, like monocyte-derived macrophages and T-lymphocytes are able to produce and secrete such mediator molecules, like cytokines, chemokines, growth-factors, enzymes, and disintegrins, which lead to activation of endothelial cells, proliferation of smooth muscle cells, lesion progression, and finally to the weakening of a vulnerable plaque by matrix degradation of its fibrous cap. Today, many of these molecules involved can be measured systemically by sensitive assays, and elevated concentrations in the circulation have been shown to be associated with future cardiovascular events. Determination of several of these molecules carries important prognostic information, independent of traditional risk factors, and may turn out to be useful in improving risk stratification. However, for most of these biomarkers the clinical utility has not yet been established.
KW - Animals
KW - Atherosclerosis/metabolism
KW - Biomarkers/metabolism
KW - C-Reactive Protein/metabolism
KW - Carotid Stenosis/metabolism
KW - Chemokines/metabolism
KW - Cytokines/metabolism
KW - Disintegrins/metabolism
KW - Humans
KW - Intercellular Signaling Peptides and Proteins/metabolism
KW - Risk Factors
KW - Rupture, Spontaneous/metabolism
U2 - 10.1161/01.ATV.0000251503.35795.4f
DO - 10.1161/01.ATV.0000251503.35795.4f
M3 - SCORING: Review article
C2 - 17082488
VL - 27
SP - 15
EP - 26
JO - ARTERIOSCL THROM VAS
JF - ARTERIOSCL THROM VAS
SN - 1079-5642
IS - 1
ER -